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ARTICLE
A MAFG-lncRNA axis links systemic nutrient
abundance to hepatic glucose metabolism
Marta Pradas-Juni et al.#
Obesity and type 2 diabetes mellitus are global emergencies and long noncoding RNAs
(lncRNAs) are regulatory transcripts with elusive functions in metabolism. Here we show that
a high fraction of lncRNAs, but not protein-coding mRNAs, are repressed during diet-induced
obesity (DIO) and refeeding, whilst nutrient deprivation induced lncRNAs in mouse liver.
Similarly, lncRNAs are lost in diabetic humans. LncRNA promoter analyses, global cistrome
and gain-of-function analyses confirm that increased MAFG signaling during DIO curbs
lncRNA expression. Silencing Mafg in mouse hepatocytes and obese mice elicits a fasting-like
gene expression profile, improves glucose metabolism, de-represses lncRNAs and impairs
mammalian target of rapamycin (mTOR) activation. We find that obesity-repressed LincIRS2
is controlled by MAFG and observe that genetic and RNAi-mediated LincIRS2 loss causes
elevated blood glucose, insulin resistance and aberrant glucose output in lean mice. Taken
together, we identify a MAFG-lncRNA axis controlling hepatic glucose metabolism in health
and metabolic disease.
https://doi.org/10.1038/s41467-020-14323-y OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Cellular and organism-level energy homeostasis and nutri-ent partitioning are instrumental for survival. In higherorganisms, multi-organ systems evolved to react to shifts
in energy supply by storing (anabolic) or metabolizing (catabolic)
nutrients, for instance by conversion of simple sugars to storage
macromolecules like glycogen or by glucose catabolism, according
to caloric demands1. A key process for mounting appropriate
responses to altered nutrient availabilities are abundance, locali-
zation, and nutrient-induced activation of transcriptional net-
works that couple energy states to appropriate changes in gene
expression2. These ancient molecular circuits ensured survival of
animals during (historically frequent) food shortages. In contrast,
the exposure to constant calorie overload, coupled with sedentary
lifestyles, results in excess storage of nutrients, and concomitantly,
obesity and obesity-associated maladies. Globally, two billion
individuals are considered overweight or obese and exhibit
elevated risks of developing severe comorbidities such as cardi-
ovascular disease3, artherosclerosis4, type 2 diabetes mellitus
(T2D), liver steatosis, or nonalcoholic fatty liver disease (NAFLD)
and nonalcoholic steatohepatitis (NASH)5. Therefore, under-
standing how nutrient-sensitive signaling networks are controlled
during conditions of energy surplus, and whether this can be
prevented in obesity, will be instrumental in designing effective
therapies in the future.
Remarkable for living in seemingly postgenomic times, we
currently witness a paradigm shift in understanding our genomes
and the information contained therein: multinational sequencing
efforts like ENCODE6, FANTOM7, or NONCODE8, together
with increasing RNA-Sequencing (RNA-Seq) capabilities and
reduced costs, led to the intriguing discovery that, whereas only
1–2% of genomic information encodes protein-coding mRNAs,
more than 70% of DNA is transcribed across developmental
space and time9,10. This led to the identification of thousands of
microRNAs, and more recently, long noncoding RNAs
(lncRNAs)11,12 in mice and humans13. The identification of these
many lncRNAs in silico and ascribing a specific function to each
has been challenging14. Functions identified to date include
microRNA scavenging15, chromatin sequestration16, 3D genome
organization17, chromatin modifier recruitment18, lncRNA–DNA
triplex formation19, and small-molecule protein complex forma-
tion20 to control mRNA translation15 and RNA–RNA crosstalk21.
Investigators have only begun to ascribe specific in vivo func-
tions for lncRNAs in cellular energy homeostasis and/or meta-
boregulatory signaling circuits. Such functions of lncRNAs include
control of hepatic cholesterol biosynthesis22, de novo lipogenesis
and systemic lipid homeostasis23,24, beta-oxidation25, glucose
homeostasis26,27, and regulation of insulin sensitivity in the liver27.
Understanding the molecular details of these regulatory processes
may lead to innovative approaches where repression of specific
lncRNAs may prove useful in the treatment of metabolic diseases.
By performing RNA-Seq in mouse models for dietary and
genetic obesity, T2D, and livers from diabetic human patients,
we find that nutrient excess and refeeding (RF) favors lncRNA
repression, whereas fasting induces lncRNA expression. Intri-
guingly, protein-coding mRNAs are not affected accordingly. In
silico analyses of lncRNA and mRNA promoters, and integra-
tion of MAFG ChIP-Seq with MAFG gain-of-function RNA-
Seq data confirm that elevated MAFG signaling in obesity and
RF is transcriptionally linked to lncRNA repression. In vitro
and in vivo loss of MAFG in hepatocytes controls glucose
production, improves glucose metabolism during obesity, and
induces lncRNAs, whereas MAFG gain of function represses
hepatic lncRNAs. Intriguingly, MAFG loss prevents insulin-
evoked activation of mTORC1 signaling, thus presumably
interfering with protein translation in hepatocytes. We further
observe that obesity-repressed LincIRS2 is negatively controlled
by MAFG and CRISPR–Cas9-mediated knockout, or antisense-
mediated RNA interference of LincIRS2 causes hyperglycemia,
insulin resistance, likely caused by alterations in glucogenic
gene expression in lean mice.
Results
Nutrient states elicit opposing effects on mRNA and lncRNAs.
To identify lncRNAs that are implicated in the development of liver
disease pathologies in diet-induced obesity (DIO), for instance
insulin resistance, steatosis, and liver inflammation, 6-week-old
C57BL/6N mice were fed a high-fat diet (HFD) or control diet
(CD). After 30 weeks, hepatic RNA was isolated and total RNA-
Sequencing (RNA-Seq) performed. This approach identified 583
mRNAs and 50 lncRNAs that were significantly (p value (pV) < 0.05
by Student’s t test, false-discovery rate < 0.05, and CuffDiff function
significant= “yes” for Benjamini–Hochberg correction for multiple
testing) altered after HFD feeding (Fig. 1a, Supplementary Data 1).
Performing Ingenuity Pathway Analysis (IPA) confirmed activation
of transcription factor (TF) networks and signaling pathways known
to be induced in the liver under anabolic/nutrient-rich conditions.
These included insulin receptor (IR), Forkhead Box O1 (FOXO1),
and Sterol Regulatory Element Binding Transcription Factor 1C
(SREBP1C) pathways (Supplementary Fig. 1a–c). We interpreted
these transcriptional changes as a reflection of chronic nutrient
exposure that in turn triggers anabolic TF pathways in the liver.
When performing differential gene expression (DGE) analysis
independently for protein-coding or lncRNA transcripts (gene
biotypes from Ensembl Biomart28), we observed a significant
cumulative downregulation of lncRNAs as compared with
protein-coding mRNAs (Fig. 1c) in obese livers using nonpara-
metric Kolmogorov–Smirnov tests. Prompted by this difference
in mRNA vs. lncRNA regulation after HFD feeding, we repeated
the analysis after physiological nutrient changes outside of
obesity and metabolic disease. Comparing transcriptomes
from ad libitum (AL)-fed C57BL/6N (wild-type) mice compared
with mice fasted for 16 h (FA, Fig. 1b, Supplementary Data 2),
we observed 1165 mRNAs and 92 lncRNAs differentially
regulated. In contrast to lncRNA repression in obesity, lncRNAs
were induced after fasting when compared with mRNAs
(Fig. 1d). Short-term (6 h) RF altered 587 mRNAs and 59
lncRNAs (Supplementary Data 3) with similar trends for
induction of lncRNAs as compared with mRNAs (Supplemen-
tary Fig. 1d). We performed RNA-Seq in BKS.Cg-Dock7m+/+;
LepRdb/J (termed LepRdb) mice, a genetic model of obesity and
T2D, and observed 959 mRNAs and 83 lncRNAs significantly
changed (Supplementary Data 4). Again, hepatic lncRNAs were
decreased compared with mRNAs (Supplementary Fig. 1e) when
we compared LepRdb vs. genetic background-matched misty
(Dock7m) mice, although to a lesser degree than in DIO. To
determine whether similar patterns are observed in human
subjects, we analyzed RNA-Seq data from liver biopsies from
a cohort of lean, obese (without T2D), and obese, T2D patients
(n= 4 per group)29. Consistent with our mouse studies, obesity
and T2D in humans were associated with repressions in
lncRNAs vs. mRNAs (Fig. 1e, f and Supplementary Data 5).
To determine if our metabolically regulated lncRNAs
represent liver-enriched transcripts, we performed RNA-Seq
in seven tissues of lean C57BL/6N mice and identified clusters
of lncRNAs enriched in each tissue (Supplementary Fig. 1f).
Within the liver-enriched cluster, seven DIO-associated
lncRNAs (termed L-DIO-lncRNAs), including 4833411C07Rik,
9030616G12Rik, 9030622O22Rik, B930025P03Rik, Gm10319,
Gm8883, and previously reported lncLSTR24 (Supplementary
Fig. 1g) matched our criteria: the expression of L-DIO-lncRNA
expression was confined to hepatocytes compared with
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non-parenchymal liver cell types (Supplementary Fig. 1h). With
the exception of Gm8883, L-DIO-lncRNAs were located in
the nucleus (Supplementary Fig. 1i), and with exception of
Gm10319, exhibited low protein-coding potential (using two
independent algorithms, CPAT30 and CPC14, Supplementary
Fig. 1j, k). Using quantitative polymerase chain reaction (qPCR)
we confirmed L-DIO-lncRNAs to be reduced by HFD vs. CD
feeding (Fig. 1g), in LepRdb vs. Dock7m (Fig. 1h), in AL vs. FA
(Fig. 1i), and in RF vs. FA mice (Fig. 1j). Thus, our extensive
RNA-Seq analyses and qPCR validation identified an inverse
correlation of nutrient levels with lncRNAs across several
mouse models of altered energy homeostasis and metabolically
compromised humans and identified metabolically regulated
(liver-selective) lncRNAs.
a b
c d
e f
g h i j
RNA-Seq
HFD vs CD
RNA-Seq
HFD vs CD
RNA-Seq
Obese (∅TSD) vs Lean
RNA-Seq
Obese (+T2D) vs Lean
RNA-Seq
AL vs FA
RNA-Seq
AL vs FA
mRNA mRNA
150 20
15
10
5
0
20
15
10
5
0
100
Co
un
t
50
0
4.8 8.3 6.9
3
0
–3
–7
4
0
–4
–8.4
3.8
2
2
1
0
–1
–2
–3.8
–2
–4.8
1.0
All
mRNA
All
mRNA
All
mRNA
All
mRNA
All
IncRNA
All
IncRNA
All
IncRNA
All
IncRNA
0.5cf
0.0
1.0
0.5cf
0.0
2.5
CD HFD Dock7m Ad libitum 6 h Refed
p = 0.082
p = 0.067
p = 0.091p = 0.055
Fasted FastedLepRdb
2.0
***
**
**
**
***
**
**
** *
*
*** ***
*
***** ***
1.5
1.0
R
el
. I
nc
R
N
A 
ex
pr
es
sio
n
0.5
0.0
2.0 50 15
10
5
5
40
30
20
5
4
3
2
1
0
1.5
1.0
R
el
. I
nc
R
N
A 
ex
pr
es
sio
n
R
el
. I
nc
R
N
A 
ex
pr
es
sio
n
R
el
. I
nc
R
N
A 
ex
pr
es
sio
n
0.5
0.0
48
33
41
1C
07
Rik
48
33
41
1C
07
Rik
90
30
61
6G
12
Rik
90
30
61
6G
12
Rik
90
30
62
2O
22
Rik
B9
30
02
5P
03
Rik
B9
30
02
5P
03
Rik
Gm
10
31
9
Gm
10
31
9
Gm
88
83
Gm
88
83
Inc
LS
TR
Inc
LS
TR
48
33
41
1C
07
Rik
90
30
61
6G
12
Rik
B9
30
02
5P
03
Rik
Gm
10
31
9
Gm
88
83
Inc
LS
TRPc
k1
48
33
41
1C
07
Rik
90
30
61
6G
12
Rik
B9
30
02
5P
03
Rik
Gm
10
31
9
Gm
88
83
Inc
LS
TRPc
k1
1.0
0.5cf
0.0
1.0
0.5cf
0.0
1.0
0.5cf
0.0
1.0
0.5cf
0.0
1.0
0.5cf
0.0
1.0
0.5cf
0.0
–2 0
Log2R
2
–2 –11
Log2FC
2 –2 –11
Log2FC
2 –2 –11
Log2FC
2 –2 –11
Log2FC
2
–2 0
p = 2E–04 (KS)
p < 0.0001 (KS) p < 0.0001 (KS) p < 0.0001 (KS)
p < E–04 (KS)
Log2R
2 –2 0
Log2R
2 –2 0
Log2R
2
0 10 1000 52,166
Mean FPKM Mean FPKM
0 10 1000 52,166
0
L2
R
L2
R
150
100
Co
un
t
50
0
0 10 1000 52,166 0 10 1000 52,166 0 10 1000 15,339
0 10 1000 15,339 0 10 1000 15,339
0 10 1000 15,339
IncRNA IncRNA
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14323-y ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:644 | https://doi.org/10.1038/s41467-020-14323-y | www.nature.com/naturecommunications 3
Liver MAFG links high nutrient states to lncRNA repression.
Our data suggested that many lncRNAs are discordantly affected
by (patho)-physiological changes in nutrient states when com-
pared with mRNAs. We hypothesized that these differences
between mRNAs and lncRNAs could reflect differences in TF-
binding site (TFBS) occurence in promoters of both gene sets.
These differences in promoter architecture could, in turn, be
differentially transactivated by nutrient-sensitive signaling path-
ways, leading to anticorrelative regulation of lncRNAs vs. mRNAs
during obesity and T2D as observed. Our hypothesis built on in
silico analyses of chromatin-state maps31 and validation studies
in human cell lines32 that suggest preexisting promoter differ-
ences between lncRNAs and mRNAs. To identify TF pathways
that control lncRNAs and mRNAs via distinct regulatory pro-
grams, we first analyzed putative promoter sequences (−800 bp to
+100 bp around transcriptional start sites, TSS) from an extended
set of 1920 mRNAs and 149 lncRNAs affected by HFD (p value <
0.1, CuffDiff DGE output). Next, we used AME33 (MEME
suite34) to call differences in TF motif occurence between lncRNA
and mRNA promoters. Consistent with previous reports31,35, we
observed that CpG-rich motifs were overrepresented in mRNA
promoters, particularly motifs recognized by the E2F family of TF
(e.g., E2F2–E2F4). In contrast, lncRNA promoters were enriched
for MAFG:NFE2L1 (V-Maf Avian Musculoaponeurotic Fibro-
sarcoma Oncogene Homolog G:Nuclear Factor, Erythroid 2 Like 1)
motifs (Fig. 2a). This finding was consistent with reports
demonstrating that TFBS recognized by MAFG or other members
of the small MAF (smMAF) TF family (MAFF, MAFG, and
MAFK) is overrepresented in lncRNA promoters31,32,35. In a
second step and given the reported gene-repressive properties of
MAFG homodimers36,37, we wanted to exclude that MAFG
motifs occurred in lncRNA promoters simply because lncRNA
tends to be more repressed than mRNAs during DIO. We thus
performed de novo TF motif enrichment analyses of the putative
promoter sequences (−800/+100 bp around TSS) in HOMER38
separately for induced and repressed genes, and confirmed that
smMAF motifs were enriched in lncRNA promoters affected by
DIO vs. protein-coding RNAs in both gene sets (Supplementary
Fig. 2a, b). Taken together, our data suggested that MAFG, or
other smMAF TFs, is enriched in lncRNA promoters as com-
pared with mRNAs, and could elicit anticorrelative transcrip-
tional effects, for instance repress hepatic lncRNAs while, at the
same time, inducing levels of specific mRNAs.
Because smMAF TF is considered as functionally redundant39,
we next asked which smMAF constituted the prevalent liver
isoform, and presumably, exerted the strongest effect on lncRNA
repression during obesity. Using RNA-Seq, we found that Mafg
accounted for the majority of smMAF transcripts in livers from
lean C57BL/6N and Dock7m mice (Fig. 2b). Integrating RNA-Seq
analysis from mice injected with Mafg cDNA-expressing
adenoviruses (Ad-MAFG), and public MAFG chromatin immu-
noprecipitation coupled to sequencing (ChIP-Seq) datasets40,
we found that MAFG preferentially bound lncRNAs repressed
during DIO (Fig. 2c). We performed qPCR in livers from Ad-
MAFG-treated mice and confirmed that the seven L-DIO-
lncRNAs (Fig. 2d) were repressed after Mafg overexpression.
Conversely, locked nucleic acid (LNA)-mediated knockdown of
Mafg (Supplementary Fig. 2c), but not Maff or Mafk (Supple-
mentary Fig. 2c–e), in primary hepatocytes derepressed a set of
lncRNAs containing MAFG-binding sites (Fig. 2e) as determined
by ChIP-Seq (Fig. 2f). These data supported the hypothesis that
MAFG represses specific lncRNAs in DIO, suggesting MAFG as
TF whose activity changes during metabolic states. To investigate
the degree of smMAF signaling activity in lean and obese livers,
we applied ISMARA41, a web-based tool modeling genome-wide
expression changes in RNA-Seq data by predicting the underlying
combination of TFBS. As proof of principle and as expected, we
found an induction of inflammatory CEBPB and RELA-REL-
NFKB1 gene programs in obese liver (Supplementary Fig. 2f, g).
When comparing all combinations of nutrient-rich (HFD, AL,
and RF) vs. nutrient-poor conditions (CD and FA) we found that
anabolic conditions exhibited higher smMAF (NFE2:BACH1:
MAFK, MAFG:NFE2L1, and MAFF) motif activities in the liver,
while large MAFA42-dependent TFBS activities were reduced
after DIO or RF (Fig. 2g). Importantly, RNA-Seq from HFD and
Ad-MAFG-treated mice revealed a significant overlap of direc-
tional gene expression changes and overlapping gene categories
(Fig. 2h, left), while Ad-MAFG and fasting gene sets showed
anticorrelative trends (Fig. 2h, right). Finally, RNA-Seq in Ad-
MAFG livers revealed trends toward repression of lncRNAs
compared with mRNAs (Fig. 2i, Supplementary Data 6). Thus,
our data suggested that acute (RF and AL) and chronic (DIO)
nutrient exposure is associated with increased smMAF signaling,
and that gain of function of the most abundant smMAF isoform
in the liver, MAFG, resulted in preferential repression of lncRNAs
in the liver.
Hepatic MAFG links energy states to glucose metabolism.
SmMAFs recruit Cap’n’Collar protein like NFE2L1/2 (or NRF1/2)
to antioxidant response elements of xenobiotic enzymes43 to
govern bile acid homeostasis40 and hepatic lipid and amino acid
metabolism44. To determine if MAFG is required to mediate
metabolic changes during DIO, we first used an in vitro
approach: using LNA transfection, we silenced Mafg in primary
hepatocytes and observed robust suppression of Mafg mRNA
and protein (Fig. 3a). To mimic fasting or RF in vitro, we treated
cells with Forskolin plus Dexamethasone (FD) or FD combined
with insulin (Ins, termed FDI), as reported45. At baseline,
silencing Mafg increased glucose production (Fig. 3b). Treating
cells with FD increased glucose production as expected, yet
increases in glucose production remained higher when Mafg was
silenced, suggesting increased gluconeogenesis. Importantly, no
in vitro differences in hepatic insulin sensitivity were observed,
as insulin treatment reduced glucose production in control (Scr)
and Mafg LNA- treated cells to similar extents (Fig. 3b). In line
with increased glucose production, Mafg RNAi increased basal
Fig. 1 Systemic nutrient states elicit opposing effects on liver mRNA and lncRNA expression. a, b Histogram plot of read counts (top), scatter plot of
reads counts vs. log2-transformed expression ratios (Log2R, bottom) and c, d cumulative frequency distribution (Cf) of Log2R of hepatic protein-coding
mRNA (blue) and lncRNA (orange) expression changes. Data are from total RNA-Sequencing (RNA-Seq) in the liver of C57BL/6N mice after a, c HFD vs.
(vs) CD feeding (n= 3 each) or b, d ad libitum feeding (AL) vs. 16 h of fasting (FA) (n= 4 each). e Log2R Cf of mRNA (blue) and lncRNA (orange)
expression changes in the liver from lean (L) vs. obese (OB) patients without T2D (n= 4 per group). f Log2R Cf of mRNA (blue) and lncRNA (orange)
expression changes in the liver of lean (L) vs. obese patients with T2D (n= 4 per group). g–j Quantitative reverse-transcription (RT) polymerase chain
reaction (qPCR) for L-DIO-lncRNA expression in mice exposed to g HFD vs. CD feeding (n= 4–6). h Leprdb vs. Dock7m (n= 4). i AL vs. FA (n= 5 each) and
j RF vs. FA (n= 4 each). c–f Statistical differences between mRNAs and lncRNAs were assessed using nonparametric Kolgomorov–Smirnov (KS) tests.
p Values are given in the panels. Bar graphs represent mean ± s.e.m. with all data points plotted and differences in (g–j) were calculated using unpaired, two-
tailed Student’s t tests. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file. Icons in a–f were created with BioRender.com.
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gluconeogenic gene expression as evidenced by elevated fructose-
bisphosphatase 1 (Fbp1), glucose-6-phosphatase catalytic sub-
unit (G6pc), and phosphoenolpyruvate carboxykinase 1 (Pck1)
expression, and when cells were stimulated with FD, Fbp1 and
G6pc remained markedly increased (Fig. 3c). This increased
glucogenic tone was confirmed by silencing MAFG using Mafg
or control Scr LNAs in C57BL/6N mice. MAFG RNAi increased
relative glucose production during a PTT, providing in vivo
evidence of elevated gluconeogenesis (Fig. 3d). Importantly,
LNA-mediated silencing of other smMAFs (Maff and Mafk) did
not increase glucogenic gene expression (Supplementary
Fig. 2h–j), emphasizing specific roles for MAFG in controlling
hepatic glucose output. In line with unaltered suppression of
glucose production (Fig. 3b), insulin-mediated suppression of
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gluconeogenic enzymes under basal but also FD-stimulated
conditions was unchanged after Mafg loss, again supporting the
notion that Mafg loss of function does not affect insulin sensi-
tivity (Fig. 3e). Consequently, when performing Western Blot
analysis in insulin-stimulated hepatocytes in the presence or
absence of Mafg, we observed modest reductions in phosphor-
ylation of serine 473 residue of serine/threonine kinase AKT/
PKB (Fig. 3f), yet reduced phosphorylation of the serine 9 of
glycogen synthase kinase 3 beta (GSK3B, Supplementary Fig. 2k),
which is dispensible for HGP46. This suggested that IR-proximal
kinases controlling glucose output, but not more distal events,
are not affected by Mafg loss.
Another important TF pathway that translates information
about nutrient states into increases in cell proliferation and
protein translation is mammalian target of rapamycin (mTOR)47:
we found insulin-evoked induction of serine 2448 mTOR
phosphorylation (Fig. 3g) and concomitant increases in mTOR
Complex 1 (mTORC1) activity, as evidenced by mTORC1-
dependent threonine 37/46 phosphorylation of eIF4E-binding
protein 1 (p4E-BP1, Fig. 3h)48, blunted after Mafg silencing,
suggesting that MAFG supports mTORC1-dependent processes
like ribosome biogenesis and cap-dependent translation49 after
insulin stimulation. Thus, we showed that increases in MAFG
signaling (e.g., in DIO and after RF) preferentially repressed
lncRNAs in primary hepatocytes, while LNA-mediated loss of
Mafg induced lncRNAs, elicited a fasting-like expression profile,
and caused specific defects in insulin-dependent activation of
signaling pathways linked to protein translation.
MAFG loss protects from obesity-induced hyperglycemia.
Having identified MAFG as an important regulator of lncRNA
expression, and showing that Mafg repressed glucose output in
hepatocytes, we next turned to in vivo loss of function. Given the
obesity-evoked increase in MAFG signaling, we hypothesized that
Mafg loss in vivo could be metabolically favorable in DIO and
conducted Mafg knockdown by performing biweekly injections of
Mafg or Scr LNAs in CD- or HFD-fed C57BL/6N mice. Mafg
treatment was well tolerated over the duration of 12 weeks and
caused suppression of Mafg mRNA and protein expression in lean
and obese liver (Fig. 4a, f) and kidney (Supplementary Fig. 3a), but
did not affect liver Maff or Mafk expression in the liver (Supple-
mentary Fig. 3b). When studying the metabolic consequences of
Mafg silencing, we did not observe alterations in body weight
(BW) in CD (Fig. 4b) or HFD-fed (Fig. 4g) mice.Mafg knockdown
modestly reduced fasting blood glucose (p= 0.073), but did
not have an effect on blood glucose concentrations in the fed state
(Fig. 4c), improved glucose tolerance (Fig. 4d), and trended toward
improved insulin sensitivity (Fig. 4e) in CD-fed mice with mor-
e pronounced effects in obese animals (Fig. 4h–j). Indirect
calorimetric quantification of oxygen consumption, carbon dioxide
production, respiratory exchange ratios, energy expenditure, and
food intake revealed no differences between groups on either CD
or HFD (Supplementary Fig. 3c–g). No histological changes
between genotypes were observed concerning fat accumulation in
obese livers (Supplementary Fig. 3h). Collectively, these results
implicated hepatic alterations in glucose homeostasis in the
observed improvement of metabolism in Mafg LNA-treated mice.
When performing RNA-Seq analysis in CD-fed Scr LNA-treated
vs. HFD-fed Scr LNA-treated mice, we observed 218 genes sig-
nificantly altered. When we compared these gene changes to the
357 genes significantly changed by Mafg LNA vs. Scr LNA treat-
ment in HFD-fed mice, we found n= 66 genes shared between
both groups (Fig. 4k and Supplementary Data 8 and 12). Inter-
estingly, we found that genes were induced by DIO as often
reduced by Mafg LNA treatment. Particularly the DIO-associated
increase in inflammatory gene categories was repressed in Mafg-
deficient obese livers (Fig. 4k). These transcriptome analyses sug-
gested that Mafg inhibition reinstated a healthy, less inflammatory
expression profile in livers of obese mice, exemplified by trends
toward increased serum fibroblast growth factor 21 (FGF21) levels
(Fig. 4l), a hepatokine beneficial in the context of obesity in mice50.
Furthermore, we observed trends (p= 0.103) toward global
lncRNA derepression (Fig. 4m) as expected from Mafg RNAi
in vitro.
To corroborate our findings of improved metabolic control upon
Mafg silencing during obesity using independent approaches, we
repeated our RNAi studies using N-acetyl galactosamine (GalNAc)-
conjugated Mafg and Control antisense oligonucleotide (ASO)
inhibitors. In addition, given the presence of three, presumably
functionally redundant51, smMAF isoforms in the liver, we silenced
Mafg in the liver of HFD-fed C57BL/6 or global MafF−/−/MafK−/−
double-knockout (DKO) mice. After 2 weeks of initial ASO
administration, mice were fed HFD for 18 weeks. As for LNA-
evoked Mafg ablation, Mafg ASO sustainably reduced Mafg mRNA
and protein not only in the liver, but also in the kidney, vWAT, and
SKM (Fig. 4n), yet did not affect Maff and Mafk expression
(Supplementary Fig. 3i). Also similar to our previous study by using
Mafg LNAs, in the absence of overt BW changes (Fig. 4o),Mafg loss
improved insulin sensitivity (Fig. 4p, q), yet no changes in glycemia,
insulin, and triglyceride levels were observed (Supplementary
Fig. 3j). Crucially, ablating Mafg upon preexisting Maff/Mafk
deficiency resulted in further improvements in insulin sensitivity
(Fig. 4r). Thus, we here demonstrate that Mafg loss using two
independent RNAi approaches improved glucose metabolism and
insulin sensitivity, particularly in obese mice.
LincIRS2 knockdown causes insulin resistance in lean mice.
Having demonstrated that loss of MAFG not only improved
Fig. 2 Obesity-associated increase in MAFG signaling links nutrient states to lncRNA repression. a Illustration of transcription factor-binding site (TFBS)
analysis and a list of TFBS enriched in promoters of mRNAs (blue) or lncRNAs (orange) affected by HFD vs. CD feeding (n= 3 each). TFBS is from UniProbe
(U) or Jaspar (J). b qPCR of smMAF (Maff, Mafg, and Mafk) expression in C57BL/6N and Dock7m mice (n= 4 each). c Published BLRP ChIP-seq in livers of
mice transduced with adenovirus (Ad)-overexpressing BLRP-MAFG fusion proteins (GEO ID: GSE77559)40 was used as a proxy for MAFG cistromes in the
liver. BLRP-MAFG peaks per gene were determined in a ±50-kb window around the TSS (defined as ±1 bp from gene start) of expressed, induced, or
repressed lncRNAs by HFD using window function in bedtools75. d qPCR of L-DIO-lncRNAs andMafgmRNA in livers of Ad-MAFG vs. Ad-CMV mice (n= 5
each). e qPCR of lncRNA exhibiting MAFG binding within TSS ± 50 kb, as identified by BLRP-MAFG ChIP-Seq and Mafg expression after transfection of
primary hepatocytes with 100 nM Mafg or Scr LNAs, n= 4–5 experiments, each performed in triplicates. f UCSC Genome Browser with expression of
selected lncRNAs (“RNA-Seq”) and BLRP-MAFG binding (“ChIP-Seq” from Vallim et al.40) in the liver. g Motif activity of smMAF and MAFA TFBS across
nutritional states and HFD feeding analyzed using ISMARA41 (n= 3–4 per group). h Venn diagram illustrating DGE overlap and enriched gene ontology (GO)
categories shared between indicated nutritional states, diets, and genotypes. i Log2R Cf of mRNA (blue) and lncRNA (orange) expression changes in livers of
Ad-MAFG vs. Ad-CMV mice (n= 4 each). d, e Bar graphs represent mean ± s.e.m. with all data points plotted, and statistical differences were calculated
using d unpaired or e paired, two-tailed Student’s t test. h Significance of gene overlaps was calculated by using a hypergeometric distribution: *p < 0.05,
**p < 0.01, ***p < 0.001. Source data are provided as a Source Data file. Illustration in (a) was created with BioRender.com.
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glucose homeostasis and insulin sensitivity but also, concurrently,
controlled lncRNA abundance in the liver, we asked if MAFG-
repressed lncRNAs are implicated in liver metabolism focused on
characterizing MAFG-dependent L-DIO-lncRNA 4833411C07Rik,
which we refer to as “LincIRS2” due to its positioning 80 kb 5′ of
Irs2 (Supplementary Fig. 4a) in the following. As expected from
our previous Mafg overexpression data, LincIRS2 was induced in
livers from Mafg LNA and Mafg ASO-treated C57BL/6N mice
(Fig. 5a). As obesity represents a complex scenario of dysregulated
glucose, insulin, lipid, and hormone homeostasis that all affect
liver energy metabolism1, we investigated which obesity-related
nutrients, hormonal factors, and nutrient-sensitive TFs, in addi-
tion to MAFG, regulated LincIRS2. For this, we expressed con-
stitutively active (ca) versions of metaboregulatory TFs in primary
hepatocytes, including glucose-sensing MLX-interacting protein
like/carbohydrate response element-binding protein (caMLXIPL/
ChREBP52), FOXO1 (caFOXO1153), or lipogenic caSREBP1C54.
We found that LincIRS2 was induced upon catabolic caFOXO1
and caChREBP expression in primary hepatocytes (Fig. 5b) in
addition to fasting–mimicking cyclic adenosin-3′,5′-monopho-
sphate (cAMP) and glucagon (GCG) stimulation (Fig. 5c). On the
other hand, insulin (with or without glucose co-stimulation)
repressed LincIRS2 (Fig. 5d), whereas IR knockout in liver induced
LincIRS2 (Fig. 5e). Concomitantly, constitutive active versions of
(insulin-dependent) SREBP1C (caSREBP1) decreased LincIRS2
expression (Fig. 5f). Thus, LincIRS2 inversely correlates with
MAFG and insulin signal transduction across several in vitro and
in vivo models of altered signaling and nutritional states.
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We next asked if, like MAFG, LincIRS2 is involved in hepatic
glucose control. LNA-mediated LincIRS2 knockdown in primary
hepatocytes was highly efficient under basal, FD, GCG, and
insulin-stimulated conditions (Fig. 5g, h). Crucially, LincIRS2-
deficient primary hepatocytes did not exhibit suppression of Pck1
expression upon insulin stimulation (Fig. 5i). These data
suggested in vitro insulin resistance upon LincIRS2 silencing as,
in contrast to Mafg, LincIRS2 RNAi did not increase Pck1
expression under basal, FD, and GCG stimulation (Fig. 5j, k).
We next investigated the consequences of LincIRS2 knockdown
in vivo by performing biweekly injections of LNAs targeting
LincIRS2. LincIRS2 silencing reduced 50% of liver and kidney
LincIRS2 in lean mice (Fig. 5l), and again, we observed no
differences in BW between genotypes in CD- or HFD-fed mice
(Fig. 5m, n). LincIRS2 LNA-treated lean mice were normogly-
cemic (Fig. 5o, left), yet mildly insulin resistant (Fig. 5o, right),
whereas LincIRS2 LNA-treated obese mice were unaffected,
presumably due to preestablished insulin resistance in these
animals (Fig. 5p). In line with this, LincIRS2 RNAi reduced
insulin-mediated AKT/PKB phosphorylation of serine 473 in
livers from lean (Fig. 5q) but not obese (Fig. 5r) mice in the
absence of changes to glucose tolerance (Supplementary Fig. 4b)
or hepatic lipid accumulation (Supplementary Fig. 4c). RNA-Seq
analysis of LincIRS2 LNA-treated livers confirmed the deteriora-
tion of metabolism at the transcriptome-wide level as DGE in
lincRS2-deficient lean mice revealed similar gene sets affected as
in Scr LNA-treated obese mice (Supplementary Fig. 4d, Supple-
mentary Data 7 and 9).
Knockout of LincIRS2 causes elevated glucose levels in mice.
Given the mild deterioration of metabolism upon transient Lin-
cIRS2 knockdown in LNA-treated mice, we wanted to address the
role of LincIRS2 in glucose metabolism using a genetic model. For
this, we employed CRISPR/Cas9 genome editing in order to target
a 418-bp region encompassing exon 1 and the putative promoter
region (marked by H3K4me3 and H3K9Ac, Supplementary
Fig. 4f–i) of LincIRS2. Sanger sequencing of the LincIRS2 allele
confirmed a 426-bp deletion, together with a 5-bp insertion of the
desired genomic LincIRS2 locus (Supplementary Fig. 4j). Homo-
zygous C57BL/6N-LincIRS2em/Cecad knockout mice (termed Lin-
cIRS2Δ/Δ) exhibited complete absence of LincIRS2 expression
(Supplementary Fig. 4k), were born at Mendelian frequencies, and
exhibited no developmental or behavioral abnormalities, changes
in BW, energy expenditure, or substrate mobilization (Supple-
mentary Fig. 4l–n). Lean LincIRS2Δ/Δ mutants exhibited elevated
blood glucose levels under fasted and fed conditions (Fig. 6a) and
glucose levels remained high after insulin (Fig. 6b) or glucose
challenge (Fig. 6c). Interestingly, LincIRS2Δ/Δ mice showed ele-
vated gluconeogenic G6pc, Pck1, and Foxo1 (Fig. 6d), oxidative
Acyl-CoA Oxidase 1 (Acox1) and Carnitine Palmitoyltransferase
1A (Cpt1a, Fig. 6e), insulin receptor substrate (Irs) 1 and 2 (Fig. 6f),
and Slc2a1-2 glucose transporter expression (Fig. 6g), suggesting
altered transcriptional regulation of these enzymes underlying the
elevated glycemia in these mice.
Finally, and to test if LincIRS2 synergized with MAFG
function, we overexpressed Mafg using adeno-associated viruses
in C57BL/6 and LincIRS2Δ/Δ mice. Adeno-associated virus
serotype 8 (AAV8)-mediated overexpression (AAV8-MAFG)
increased Mafg mRNA and protein (Fig. 6h), but did not alter
fasted or random-fed glucose levels (Fig. 6i, j). Intriguingly
though, driving Mafg, alone or coupled to LincIRS2 loss, again
caused glucose intolerance to similar extents, arguing for
synergistic roles of MAFG overexpression and LincIRS2 deletion
(Fig. 6k, l) in glucose metabolism. Conversely, delivery of Mafg
alone caused insulin resistance (Fig. 6m), but not when coupled
to LincIRS2 loss (Fig. 6n), suggesting independent roles in
regulating insulin sensitivity. Taken together, our data identified
a transcriptional pathway where MAFG acts as a repressor
of metabolically regulated hepatic lncRNAs. We identified
a specific MAFG-repressed lncRNA, LincIRS2, that contributed
to glucose homeostasis and insulin-mediated suppression
of hepatic glucose production in mice. Either genetic LincIRS2
deletion or LincIRS2 RNAi in vivo impaired glucose metabolism,
albeit to different degrees, and presumably, via different mole-
cular mechanisms.
Collectively, we demonstrated a hitherto unknown role for
MAFG in serving as intracellular sensor of systemic nutrient
states, where changes in MAFG signal transduction are coupled
to alteration of hepatic glucose homeostasis. Further, increased
MAFG signaling partly explained the initial observation of
opposite regulation of lncRNAs vs. mRNAs during DIO and
T2D. One molecular effector mechanism of how excessive
MAFG activity during DIO translated into glucose alterations
is repression of liver-selective LincIRS2, which itself integrated
anabolic and catabolic metabolites and TF responses (illu-
strated in Fig. 6o). In vivo genome editing and RNAi against
LincIRS2 revealed roles for this MAFG-lncRNA axis in
ensuring hepatic glucose handling and maintenance of insulin
sensitivity.
Discussion
Our results establish the TF MAFG as a regulator of energy-rich
nutrient states in the liver, both in postprandial responses and
during metabolic diseases like obesity and type 2 diabetes.
Fig. 3 MAFG signaling in hepatocytes represses glucose production and supports mTOR activation. a Representative MAFG immunoblot and Mafg
expression after transfection of primary hepatocytes with 100 nM Mafg or Scr LNA. b Relative glucose levels in primary hepatocytes after transfection with
100 nM Mafg or Scr LNAs and stimulation for 24 h with 10 µm Fsk plus 100 nM Dex (FD) or FD combined with 100 nM insulin (FDI). c, e Indicated mRNAs
after transfection with Mafg or Scr LNAs under basal conditions or stimulated with c 10 µM Fsk plus 100 nM Dex (FD) or e 100 nM insulin. Data represent
a n= 5 or b, c, e n= 3–4 independent experiments, each performed in triplicates. d Pyruvate tolerance test (PTT) performed in C57BL/6N mice after
6 weeks of HFD feeding with 10 mg kg−1 of Mafg (n= 9) or Scr (n= 8) LNA injected 5 days before. f–h Immunoblots of f total and Serine 473
phosphorylated AKT/PKB (pAKTS473). g Total and Serine 2448 phosphorylated mammalian target of rapamycin (pmTORS2448) and h total and Threonine
37/46 phosphorylated eukaryotic translation initiation factor 4E binding protein 1 (p4EB-BP137/46) after transfection of primary hepatocytes with 100 nM
Mafg or Scr LNAs and stimulated for 10 min with vehicle (v.e.) or 100 nM insulin. Separate membranes were loaded with equal amounts of protein lysate
for total and phospho-specific immunoblotting, and equal loading was confirmed by calnexin (CLNX) for each membrane. Due to different molecular
weights of mTOR, PKB/AKT, and 4E-BP1, these proteins were partly investigated on the same membranes together with the same CLNX antibody. CLNXa
and CLNXb bands are therefore identical. Each blot is representative of n= 3 immunoblots, each immunoblot performed after transfection of Mafg vs. Scr
LNA in hepatocyte preparations from n= 2 mice. a–c, e Bar graphs represent mean ± s.e.m. with all data points plotted and statistical differences were
calculated using a paired, two-tailed Student’s t test. b, c, e One-way ANOVA and d two-way ANOVA with Bonferroni post correction for multiple testing.
Superscripts depict group comparisons for post analysis (a–f= comparison vs. column 1–6). d Box plot bounds depict upper and lower quartiles with
median as the center. Whiskers span all values: *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
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Mechanistically, we demonstrated that MAFG controls a specific
set of obesity-associated hepatic lncRNAs that are repressed in
obese livers, in addition to the known function of MAFG in bile
acid regulation40.
Our results show little evidence for co-regulation with only
four disease-associated syntenically conserved lncRNAs in human
and mouse livers (Supplementary Data 13) when performing
comparative lncRNA analyses using PLAR55. This may be due to
(1) misannotation of gene biotypes, as not every lncRNA tran-
script truly represents a noncoding transcript, evidenced, e.g., by
the high protein-coding potential of lncRNA Gm10319, (2) due to
the fact that lncRNA conservation at the structural and function
level is hard to address computationally56, or (3) conservation of
disease-associated lncRNAs simply is low as shown in other cell
types57. Another caveat lies in the low number of obesity-
associated lncRNAs we identified here. This limits the statistical
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power of TF motif enrichment algorithms. However, other in
silico studies came to similar conclusions in terms of smMAF
TFBS enrichment in long noncoding RNA promoters31,32,35.
In our study, we found that MAFG signaling activity was
reduced during fasting, which has not been previously reported.
We then analyzed both MAFG and its known interaction partner
NRF1/NFE2L1 during nutrient deprivation and found that, while
both Nrf1/Nfe2l1 and Mafg mRNA were mildly induced, NRF1/
NFE2L1, but not MAFG protein, was profoundly upregulated
during fasting (Supplementary Fig. 5a, b). By reanalyzing publicly
available hepatic RNA-Seq data performed in mice with
hepatocyte-specific deletion of NRF1/NFE2L158 (GEO ID:
GSE103949), we found that NRF1/NFE2L1 ablation resulted in
strikingly similar expression profiles compared with MAFG
overexpression (Supplementary Fig. 5c). These data suggested
that the interaction of MAFG with NRF1/NFE2L1 constitutes an
important regulatory step during fasting in the liver: recruitment
of MAFG into NRF1/NFE2L1:MAFG heterodimer complexes, for
instance after fasting-induced increases in NRF1/NFE2L1 protein
would, in turn, reduce MAFG target gene expression (as during
fasting), consistent with a notion where NRF1/NFE2L1 deficiency
and MAFG overexpression increase pools of “free” MAFG
homodimers with known gene-repressive functions36,37.
Although we have not directly addressed the binding partners of
MAFG under different nutrient stress conditions, our data sug-
gest that competition between NRF1/NFE2L1 and MAFG is
important for liver physiology: as found for MAFG gain of
function40, NRF1/NFE2L1 inactivation in the liver downregulated
genes involved in cholesterol to bile acid conversion, e.g.,
Cyp7b158. This suggests that, whereas NRF1/NFE2L1 suppresses
inflammation and promotes bile acid synthesis40, MAFG over-
expression induces hepatic inflammation (Fig. 5k) and suppresses
bile acid conversion40, in addition to suppressing key regulatory
lncRNAs such as LincIRS2 (Supplementary Fig. 5d, e and Sup-
plementary Data 11). Whether the MAFG-dependent regulation
of lncRNAs (e.g., LincIRS2), or the MAFG-dependent regulation
of coding mRNAs are key in mediating the MAFG-dependent
changes in energy-rich nutrient states remains to be determined.
However, our data suggest that the MAFG-dependent regulation
of coding and noncoding mRNAs is complimentary, suggesting
that both are required to elicit the full response.
Ultimately, our findings could also indicate that MAFG path-
way inhibition, or NRF1/NFE2L1 activation, could generally
favor energy-preserving processes where transcription of long
noncoding RNAs does not require subsequent mRNA translation.
Conversely, postprandial or obesity-associated activation of
MAFG would trigger energy-demanding, anaplerotic processes
like an increase in cellular proliferation and protein synthesis as a
consequence of mTOR-4E-BP1 pathway activation.
Methods
Animal care and research diets. All animals were maintained on a C57BL/6N
background, housed in groups of 3–5 animals per cage at 22–24 °C on a constant
12-h light/dark cycle in a SPF-controlled facility with regular testing for patho-
gens. Care of animals and all mouse research was approved by and we adhered to
institutional and animal-care committee ethical guidelines from local (Bezirks-
regierung Köln) or regional (Tierschutzkommission accession no. §15 TSchG of
the Landesamt for Natur, Umwelt und Verbraucherschutz (LANUV) North-
Rhine Westphalia, Germany, internal reference no. Az-84-02.04-2016.A460)
authorities. Upon weaning, mice were fed standard rodent chow (Teklad Global
Rodent T.2018.R12; Harlan). For experiments involving controlled feeding
paradigms, animals were allowed AL access to CD (D12450B* mod LS; Sniff)
containing 62 kJ% carbohydrates, 27 kJ% protein, and 11 kJ% fat and drinking
water. DIO was achieved by feeding a HFD (D12492 (I) mod; Sniff) containing
22 kJ% carbohydrates, 24k J% protein, and 54 kJ% fat from starting at 6–7 weeks
of age. Experimental mice were exposed to specific diets for 10–12 weeks and
17–18 weeks old at sacrifice unless described otherwise. Six-month-old LIRKO59
(Albumin-Cre+/−, IRflox/flox) and littermate control (Albumin-Cre−/−, IRflox/flox)
animals were used.
RNA isolation and total RNA-Sequencing. Liver samples used for total RNA-
Sequencing (RNA-Seq) were from male, 36-week-old C57BL/6N mice exposed to
CD (n= 3) or HFD (n= 3) feeding for 30 weeks, starting at 6 weeks of age. RNA-
Seq of C57BL/6N liver mice exposed to different nutrient states was performed in
liver samples from male, 17-week-old, lean AL (n= 4), AL followed by 16 h of
fasting (FA, n= 4), and FA followed by 6 h of RF (n= 4) mice. For RNA-Seq from
a genetic model of obesity and T2D, male BKS.Cg-Dock7m+/+; LepRdb/J (db/db)
mice and BKS.Cg-Dock7m+/+ (misty/misty) control mice were purchased from
Jackson Laboratory or Janvier Labs. We used misty mice as control animals, as
they are the littermates of db/db mice generated on the BKS.Cg-Dock7m+/+
LepRdb/J background (n= 4 mice per genotype). Tissues were collected at
10 weeks of age. RNA-Seq was also performed in lthe iver from mice treated with
adenoviruses expressing Mafg cDNA (Ad-MAFG, n= 3) or empty vector (Ad-
CMV, n= 3) under control of mouse cytomegalovirus (CMV) promoter40. Briefly,
cDNAs for mouse MAFG, were cloned from whole-liver cDNA into pAdTrack
CMV plasmids. For animal experiments, 1× 10E9 plaque-forming units were used,
and tissues were collected after 5–7 days of viral treatment. RNA-Seq was also
performed in the liver from 21-week-old male mice exposed to CD or HFD and
injected 15 weeks with control (Scr), Mafg, or LincIRS2 LNA (n= 4 per genotype
and diet). Human liver samples used for RNA-Seq were obtained from male
individuals that were with lean and nondiabetic (n= 4; age 60.75 ± 9, body mass
index (BMI) 23.52 ± 1.36, Patient IDs: 11_ 0381WSC, 13_1651HRU,
135_1311WER, and 155_3141AZE), obese and nondiabetic (n= 4; age 38.5 ±
13.42, BMI 51 ± 2.98, Patient IDs: 31_0311RAN, 32_0861NSC, 37_1941JRO, and
98_0121STR), overweight, diabetic (n= 2; age 75.5 ± 0.7, BMI 26 ± 1.41, Patient
IDs: 54_0951LZU, 56_1781DGR, 95_1701GBO, and 152_3011FHE), and obese
and diabetic (n= 2; age 44 ± 2.8, BMI 48.25 ± 20.85). All patients gave written
informed consent, and approval of the ethics committee of the University of Ulm
was obtained29. Library preparation and sequencing was performed at (1) Max-
Planck Genome-Centre (MP-GC, HFD vs. CD cohort) or (2) the Cologne Center
for Genomics (CCG), Germany (others). Following quality checks, 1 µg of total
liver RNA of each sample was (1) depleted for rRNA using NEBNext® rRNA
depletion Kit (human/mouse/rat). Library preparation was performed with
NEBNext Ultra™ Directional RNA Library Prep Kit for Illumina (New England
Biolabs) or (2) depleted for cytoplasmic and mitochondrial rRNA with Ribo-Zero
Gold (LNA Cohort) or Ribo-Zero and strand-specific library preparation per-
formed using TruSeq RNA Gold Kit from Illumina. All libraries were sequenced
on (1) HiSeq2500 in 2 × 100-bp PE or (2) HiSeq 4000 instruments in 2 × 75 PE
sequencing mode.
Fig. 4 MAFG loss protects from obesity-induced hyperglycemia. a qPCR of Mafg expression in the liver from CD-fed 21-week-old C57BL/6N mice after
15 weeks of 10 mg kg−1 of Mafg (n= 8) or Scr LNA (n= 7) and immunoblot of MAFG and CLNX protein. b Body weight, c 16-h fasted, and random-fed
glucose, d GTT, e ITT in CD-fed C57BL/6N mice after 6 and 5 weeks of Mafg or Scr LNA (n= 8). f qPCR of Mafg expression in the liver from 21-week-old
HFD-fed mice after 15 weeks of Mafg or Scr LNA (n= 8). g Body weight, h 16-h fasted, and random-fed glucose, i GTT, and j ITT in HFD-fed C57BL/6N
mice after 6 and 5 weeks of Mafg or Scr LNA (n= 8). k DGE overlap and enriched categories in livers from CD- or HFD-fed C57BL/6N mice after
10 weeks of Mafg or Scr LNA (n= 4). l FGF21 levels from 21-week-old HFD-fed C57BL/6N mice after 15 weeks of Mafg (n= 8) or Scr LNA (n= 7).
m Log2R Cf of mRNA and lncRNA expression changes in 21-week-old HFD-fed mice after 15 weeks of Mafg or Scr LNA (n= 3). n qPCR of Mafg
expression in liver and indicated tissues after 20 weeks of 5 mg kg−1 Mafg or Control ASO (n= 7 Mafg and n= 10 Control ASO in liver, n= 4 other
tissues) and immunoblot of MAFG and CLNX in the liver of HFD-fed C57BL/6N mice after 2 days of Mafg or Control ASO. o BW in 16-week-old HFD-fed
mice after 10 weeks of Mafg or Control ASO (n= 7 Mafg and n= 10 Control ASO). Absolute p relative q, r glucose during ITT in HFD-fed p, q C57BL/6N
or r Maff/Mafk−/− (DKO) mice after 11 weeks of Mafg or Control ASO (n= 6 Control ASO, n= 9 Mafg ASO, and n= 6 Mafg ASO in DKO). Bar graphs
represent mean ± s.e.m. with all data plotted and statistical differences calculated using a, c, f, h, n unpaired, two-tailed and l unpaired, one-tailed
Student’s t test. m Kolgomorov–Smirnov b, d, e, g, i, j, p–r two-way ANOVA with Bonferroni post correction. k Significance of gene overlaps was
calculated by using a hypergeometric distribution: *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
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RNA-Sequencing data processing.
(1) Mouse RNA-Seq was processed utilizing the GRCm38 assembly of the
mouse genome as gene sets from Ensembl release 9060. Biotype and gene
features were added manually using Ensembl Biomart. The pipeline consists
of six steps: (i) barcode and adapter removal using flexbar 3.4.061, (ii)
computational rRNA depletion by filtering reads that map to known rRNAs
in mice using Bowtie2 2.2.962, (iii) alignment of non-rRNA reads to the
mm10 reference genome using STAR 2.6.0c63, (iv) transcript assembly using
cufflinks followed by (v) cuffmerge, and (vi) cuffdiff performs DGE analysis
between experimental conditions via Cufflinks suite 2.2.164.
(2) Human RNA-Seq data were analyzed using QuickNGS65, version 1.2.2,
based on Ensembl release 82. In brief, reads were mapped to GRCm38
assembly of the human genome using Tophat266, version 2.0.10, and
reassembled with Cufflinks, version 2.1.1. DGE was analyzed using the
DESeq267, version 1.10.1. The results were uploaded to the QuickNGS
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database and combined with multiple annotations using the biomaRt
package version 2.16.0.
Gene overlap analysis. Overlap of regulated gene sets were performed with
“venneuler” package for R using genes defined under (1) in the paragraph above.
The p value of the overlap was calculated using hypergeometric distribution
p ¼
Xmin m;nð Þ
i¼k
m
i
 
N m
n i
 
N
n
 
where N is the total number of testable genes, m is regulated genes in study A, n is
regulated genes in study B, and k is genes overlapping studies A and B.
Ingenuity pathway analysis. IR, FOXO1, and SREBP1C/SREBF1 were loaded as
seed gene nodes into IPA and expanded into TF-dependent networks by using the
“grow” option with molecular interactions limited to “direct” and “downstream”
effects. These manually curated pathways were overlaid with DGE information
from RNA-Seq in HFD- vs. CD-fed C57BL/6N mice.
Promoter analyses and motif enrichment analysis.
(1) For enrichment analyses of known TFBS using AME33 functionality of
MEME34, RNA-Seq data of livers from mice on CD or HFD feeding were
aligned to mm10 using STAR63, and transcriptome assembly and DGE
analyses performed using CuffLinks/CuffDiff68, respectively. Significantly
altered mRNAs and lncRNAs were defined by p value ≤ 0.1 and L2R > 0 or
<0. lncRNAs and mRNAs were defined by filtering for biotypes
“bidirectional_promoter_lncRNA”, “lincRNA”, “sense_intronic”, “sense_o-
verlapping”, “antisense”, and “protein-coding” using annotations from
Ensembl Biomart Version 90. Promoter sequences (defined as −800/+100
bp from TSS) of each biotype class were extracted and enriched TFBS
motifs identified using commands “ame–verbose 1–oc–bgformat 1–scoring
avg–method ranksum–pvalue-report-threshold 0.05 db/JASPAR/JAS-
PAR2018_CORE_vertebrates_non-redundant.meme db/MOUSE/uniprobe_-
mouse.meme”.
(2) For de novo enrichment analyses of TFBS motifs using HOMER, mRNA,
and lncRNA promoter sequences from (1) were used as input for HOMER
de novo motif analyses (findMotifsGenome.pl) using indicated promoter
lists as background. De novo motif analyses were collapsed to motifs known
to bind TFs found expressed in at least one condition in the RNA-Seq data
(CD/HFD), using the curated motif list from the IMAGE pipeline69.
Chromatin-immunoprecipitation (ChIP) sequencing analysis. Previously pub-
lished public BLRP ChIP-seq data from livers of mice transduced with adeno-
viruses overexpressing BLRP-MAFG fusion protein (GEO ID: GSE77559) were
used as proxy for MAFG cistromes in the liver. The ChIP-seq data were aligned to
mm10 genome using STAR63, and BLRP-MAFG peaks were called in each replicate
(n= 2) using findPeaks function in HOMER38. The peak lists were merged using
mergePeaks function in HOMER and only peaks called in both replicates were
retained for downstream analyses.
In vivo RNAi using LNAs. RNA-interference (RNAi)-mediated silencing of Mafg
and LincIRS2 was performed using custom-made LNA GapmeRs that were
designed and synthesized by Exiqon, Denmark to target murineMafg and LincIRS2
(Mafg, LincIRS2 LNA). A negative control with no homology to known mouse
transcripts was used as control LNA. Four-week-old C57BL/6N male mice were
obtained from Charles River and acclimated for 2 weeks, followed by intravenous
(i.v.) injection of 10 mg kg−1 BW LNA dissolved in 0.9% NaCl once every other
week for 15 weeks starting from 6 weeks of age. One week after the start of
injection series, mice were placed on CD or HFD for 14 weeks. Insulin and glucose
tolerance test (ITTs and GTTs) were performed at 6 and 7 weeks of diet,
respectively.
In vivo RNAi using antisense oligonucleotides (ASO). Six- to seven-week-old
male C57BL/6N mice or Maff/Mafk-null (double knockout, DKO) mice were
injected weekly with 5 mg kg−1 Gal-Nac-conjugated Mafg or Control ASO at a
concentration of 1 mg/mL dissolved in 1× phosphate-buffered saline (PBS), for
20 weeks. Two weeks after the first injection, mice were placed on HFD for
18 weeks. ITT was performed at 9 weeks on diet, and GTT was performed at 10
and 16 weeks on diet.
Generation of LincIRS2Δ/Δ knockout mice using CRISPR/Cas9. Generation of a
mouse model for genetic LincIRS2 deficiency (LincIRS2Δ/Δ) was performed using
CRISPR/Cas9 genome editing where a 426-bp deletion (chr8:
10,899,861–10,900,279) and a 5-bp insertion, encompassing the presumed pro-
moter region (defined by occurrence of histone 3 lysine 4 trimethylation
(H3K4me3) near the LincIRS2 TSS in murine liver, based on NIH Epigenomics
Roadmap information70) and exon 1 of LincIRS2 (GRCm38/mm10) were excised.
To this end, guide RNAs (gRNAs, sequences provided in Supplementary Data 10)
were designed using CRISPOR71 and gRNAs with highest specificity scores (≥50)
chosen, yet gRNAs with predicted off-target effects for 1 or 2 occurring mismatches
excluded. After gRNA identification, target-specific CRISPR RNAs (crRNAs) were
incubated with generic transactivating crRNAs (tracrRNAs, Integrated DNA
Technologies) to form the active gRNA. Next, annealed gRNAs were incubated
with Cas9 proteins to obtain functional ribonucleoprotein complexes. Pronuclear
injections of CRISPR/Cas9 complexes into fertilized oocytes of C57BL/6N females
were performed at the CECAD in vivo Research Facility72. Briefly, we employed
pronuclear injection of CRISPR/Cas9 components into C57BL/6NRj zygotes,
which were then implanted into pseudopregnant RjHan:NMRI females. Synthetic
target-specific crRNA and sequence-independent tracrRNA molecules were pur-
chased from commercial distributors. Shortly before injection, crRNAs and
tracrRNAs were co-incubated with recombinant Cas9 proteins, and to enhance the
efficacy of CRISPR/Cas9 genome editing, we added Cas9-encoding mRNA to the
injection mix. Healthy, CRISPR/Cas9-injected oocytes were subsequently implan-
ted into oviducts of pseudopregnant 0.5 postcoital foster females. Finally, offspring
born from implanted oocytes was analyzed via DNA sequencing, and in the case of
successful CRISPR/Cas9-mediated LincIRS2 knockout, bred to C57BL/6N mice to
create C57BL/6-LincIRS2em1Cecad transgenic mouse lines. Genotyping primers are
available in Supplementary Data 10. For each of the two gRNAs, the top five sites of
predicted off-target Cas9 activity were investigated using Sanger Sequencing, and
no changes to the GRCm38/mm10 genomic sequence were detected (Supple-
mentary Data 14).
Adeno-associated virus (AAV)-mediated MAFG overexpression. PscAAV8-
MAFG-HA encoding plasmids were produced by replacing luciferase (Luc) coding
sequence in pscTTR-luc by the respective sequences. AAV8 was produced in
HEK293 cells using the triple-transfection method. Specifically, the AAV helper
plasmid pXR8, the adenoviral helper plasmid pXX6, and the vector plasmid
(pscTTR-luc, pscAAV-MAFG-HA) were transfected in 1:1:1 molar ratio using CaP
method. Forty-eight hours post transfection, cells were harvested and lysed. Fol-
lowing benzonase treatment and a low-speed centrifugation preclearing step,
preparation was purified by iodixanol step gradient purification. Genomic titer was
determined by qPCR using ITR-specific primers. C57BL/6N and LincIRS2Δ/Δ male
Fig. 5 Knockdown of MAFG-dependent LincIRS2 causes mild insulin resistance in lean mice. a qPCR of LincIRS2 expression in the liver from C57BL/6N
mice treated with Scr LNA (n= 7),Mafg LNA (n= 8), Control ASO (n= 10), orMafg ASO (n= 7). b–f qPCR for LincIRS2 expression in primary hepatocytes
after b 24 h of transduction with adenoviruses (Ad)-expressing caChREBP and caFOXO1, c 16 h of 200 nM GCG and 100 µM cAMP, d 6 h of 27.5 mM
glucose, and/or e 100 nM insulin in livers from mice with hepatocyte-specific IR knockout vs. Cre-negative Controls59 (n= 3). f Twenty-four hours after
transduction of primary hepatocytes with Ad-caSREBP1c. g qPCR of LincIRS2 expression after transfection of primary hepatocytes with 100 nM LincIRS2 or
Scr LNAs and 6 h of stimulation with g FD and GCG or h insulin. g, h n= 6–10 independent experiments, each in triplicate. i–k qPCR of Pck1 expression after
transfection with 100 nM LincIRS2 or Scr LNAs and 6 h of stimulation with i insulin, j FD, or k GCG. i–k n= 5–10 experiments, each in triplicates. l qPCR of
LincIRS2 expression in indicated tissues from 21-week-old CD-fed mice after 15 weeks of 10mg kg−1 LincIRS2 or Scr LNA (n= 4) treatment. m, n Body
weight in m CD- and n HFD-fed C57BL/6N mice during 15 weeks of LincIRS2 LNA or Scr LNA (n= 8) treatment. o Fasted and random-fed GTT and ITT in
CD-fed 12- and 11-week-old C57BL/6N mice after 6 and 5 weeks of LincIRS2 or Scr LNA (n= 8) treatment. p Fasted and random-fed glucose and ITT in
HFD-fed 12- and 11-week-old C57BL/6N mice after 6 and 5 weeks of LincIRS2 or Scr LNA (n= 8 each) treatment. q, r Representative immunoblot and
densitometry of t-AKT and pAKTS473 in p CD- or r HFD-fed C57BL/6N mice after 15 weeks of LincIRS2 or Scr LNA treatment injected with 2.5 µl g−1 BW
NaCl 0.9% or 0.1 U/mouse insulin (n= 3). Bar graphs represent mean ± s.e.m. with all data plotted and statistical differences calculated using (a–i),
l unpaired, two-tailed Student’s t test. q One-way ANOVA or m–p two-way ANOVA with Bonferroni post correction for multiple testing. *p < 0.05, **p <
0.01, ***p < 0.001. Source data are provided as a Source Data file.
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mice were 8–10 weeks of age and i.v. injected with 10E11 vector particles/animal of
genomic copies for AAV control (encoding Luc) or AAV-MAFG. Glucose and
insulin tolerance test were performed at 8 and 9 weeks after injection.
Isolation of primary hepatocytes and liver fractionation. Mouse primary
hepatocytes were isolated from C57BL/6N mice livers by a classical two-step
collagenase perfusion method73 with minor modifications as follows: mice were
subjected to experiments around 8–12 weeks of age. Under anesthesia, mice were
perfused via the portal vein with 50 ml of perfusion medium, followed by digestion
with 50 ml of collagenase medium. After liver perfusion, dissociated cells from the
liver were filtered through a 70-µm cell filter (BD Falcon) into DMEM, low glucose
(Gibco) supplemented with 10% FBS and 1% penicillin–streptomycin (P/S), and
centrifuged twice at 50g for 3 min to recover the pellet and the supernatant.
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Hepatocytes were obtained by resuspending the pellet in 30% Percoll and cen-
trifuging at 150g for 7 min. For obtaining non-hepatocyte (non-parenchymal) cell
fractions, the supernatant was centrifuged at 350g, and the resulting cell pellets
centrifuged on a 20% (w/vol) Histodenz (Sigma) gradient. For fractionation ana-
lyses, both hepatocytes and non-parenchymal fractions were frozen immediately
after isolation. For experiments in which hepatocytes were transfected and/or sti-
mulated, cells were attached to six-well collagen I-coated plates (Costar) for 2 h and
were grown in P/S-supplemented DMEM, low glucose (Gibco) without FBS
overnight; they were then subjected to experimental procedures 24 h after isolation.
The media were as follows: Perfusion medium, HBSS (Gibco) without magnesium
or calcium and supplemented with 0.5 mM EGTA; collagenase medium, DMEM,
low glucose (Gibco) supplemented with 15 mM HEPES and 100 collagen digestion
units (CDU)ml−1 of collagenase, type IV (Worthington); 90% concentrated Per-
coll, 100% Percoll (Amersham) diluted with 10× HBSS (Gibco).
Subcellular fractionation of primary hepatocytes. Subcellular fractions were
obtained using freshly isolated primary hepatocytes using Nuclei Isolation Kits:
Nuclei EZ Prep according to the manufacturer’s (Sigma Aldrich) protocol. Briefly,
5 × 106 cells were centrifuged (5 min, 300g, 4 °C) and supernatants were discarded,
whereas cell pellets were resuspended in 10 ml of PBS and centrifuged again (5 min,
300g, 4 °C). After removal of supernatants, 4 ml of ice-cold Nuclei EZ Lysis Buffer
was added to cell pellets and the reaction tube vortexed briefly and kept on ice for
5 min. Following centrifugation (5 min, 300g, 4 °C), supernatants were kept for
later analysis (cytoplasmic fraction), while pellets were resuspended in 4 ml of ice-
cold Nuclei EZ Lysis Buffer, vortexed briefly, and kept on ice for 5 min. After a final
centrifugation (5 min, 300g, 4 °C) supernatants were discarded and nuclei pellets
resuspended in 200 µl of ice-cold Nuclei EZ Storage Buffer (nuclear fraction). If not
directly processed for RNA isolation, cytoplasmic and nuclear fractions were stored
at −80 °C.
LNA-mediated gene knockdown of primary hepatocytes. Primary hepatocytes
from C57BL/6N mice were cultured for 24 h at 37 °C and 5% CO2 before trans-
fection of control (Scr), Mafg, and LincIRS2 (4833411C07Rik) LNAs (sequences
provided in Supplementary Data 10). Lipofectamine RNAiMax was diluted 1:16 in
DMEM. For a final concentration of 100 nM, the respective LNAs (stock 10 µM)
were diluted 1:100 in DMEM. Both solutions were incubated for 5 min at room
temperature. LNA and Lipofectamine solutions were mixed at equal volumes and
incubated for 5 min. Cells were washed with prewarmed 1× PBS and 1.6 ml of
DMEM without FBS added to each well. Four-hundred microliters of LNA/Lipo-
fectamine mix was added and cells incubated for 24 h at 37 °C and 5% CO2 before
changing the medium. For in vitro stimulation experiments, primary hepatocytes
were washed with prewarmed 1× PBS and fresh medium added. Cells were sti-
mulated with 100 nM Insulin (Sigma), Glucagon (0.1 mg ml−1, Sigma), 10 µM
Forskolin plus 100 nM Dexamethasone (FD), or FD plus 100 nM Insulin (FDI),
and incubated for 10 min, 6 h, or 24 h at 37 °C and 5% CO2, before harvesting cells
for further experimental analysis.
Quantification of glucose production. After 24 h of transfection, primary hepa-
tocytes were washed with warm 1× PBS, and glucose-free DMEM (Gibco) sup-
plemented with 100 mM sodium pyruvate was added in order to study cell-
intrinsical glucose production. Stimulation with Fsk/Dex (10 µM/100 nM) with/
without 100 nM insulin was performed for 24 h at 37 °C and 5% CO2. Supernatant
medium of the cells was collected to measure endogenous glucose production with
Glucose-Glo Assay Kits (Promega) following the manufacturer’s instructions.
Adenoviral overexpression of metabolic TF in hepatocytes. Adenoviruses
encoding YFP (Addgene plasmid #15302), constitutively active mouse FOXO1
(caFOXO1, Addgene plasmid #17547), and constitutively active mouse SREBP1c
(caSREBP1C, Addgene plasmid #8883) were subcloned from plasmids (Addgene)
into the adenoviral vector system pAd/CMV/V5-DEST™ (Invitrogen). A con-
stitutively active mouse ChREBP lacking the N-terminal low-glucose inhibitory
domain was PCR amplified from mouse liver cDNA74 and cloned into pAd/CMV/
V5-DEST. Adenoviruses were amplified in HEK293A cells and purified by CsCl
gradient centrifugation. Purified viruses were desalted with PD10 columns (GE
Healthcare Life Sciences) and were titered with an Adeno-X Rapid Titer Kit
(Clontech). Primary hepatocytes were treated with adenoviruses encoding afore-
mentioned TF for indicated times. For in vitro stimulation experiments, cells were
exposed to 100 µM cAMP or 200 nM GCG and incubated for 6 h or stimulated
with 100 nM Insulin (Sigma) for 16 h, at 37 °C and 5% CO2, before harvesting cells
for experimental analysis.
Immunoblot analysis. For protein isolation, primary hepatocytes grown on six-
well plates were washed gently one time with ice-cold 1× PBS and excess 1× PBS
aspirated. Five-hundred microliters of RIPA lysis buffer (50 mM Tris-HCL, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.1% sodium deoxycholate, 1% NP-40, 1× protease
inhibitor (Sigma), and 1× phosphatase inhibitor (Roche)) was added to each well of
the six-well plate and cells were scraped. Protein lysates were transferred to 1.5-ml
Eppendorf tubes, snap-frozen in liquid nitrogen, and thawed on ice for three
repeated cycles. Tissues were homogenized in 1 ml of RIPA Buffer using FastPrep
24G (MPBio). After 10 min of centrifugation at 12,000g and 4 °C, the supernatant
was collected into fresh tubes, and protein concentration was determined using the
Bradford colorimetric protein method (Thermo Fisher Scientific). Protein samples
were stored at −80 °C. Samples for immunoblotting were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis after being prepared with 4×
Laemmli Sample Buffer containing 10% β-mercaptoethanol and heated to 95 °C for
5 min. Subsequently, proteins were transferred to nitrocellulose membrane and
blocked with Western Blocking Reagent (Roche). Membranes were incubated with
primary antibodies at 4 °C overnight. After incubation with secondary antibodies,
blots were developed with Pierce ECL Western Blotting substrate (Thermo Fisher
Scientific). All densiometric measurements were performed with ImageJ. Band
intensity was normalized to calnexin (CLNX), which served as internal loading
control, blotted on the same gel and membrane. Antibodies were purchased from
Cell Signaling Technology and raised against pAKTS473 (Catalog No. 9271), t-AKT
(Catalog No. 4685), pTORS2448 (Catalog No. 2971), t-mTOR (Catalog No. 2972),
p4E-BP1T37/46 (Catalog No. 2855), t-4E-BP1 (Catalog No. 9452), pGSK3BS9
(Catalog No. 9323), t-GSK3B (Catalog No. 9315), and NRF1/NFE2L1 (Catalog No.
8052). MAFG antibody was purchased from GeneTex (GTX 114541). Primary
antibodies were used at a 1:1000 dilution ratio in Tween TBS. CLNX antibody was
used at a 1:5,000 dilution and purchased from Calbiochem (Catalog No. 208-880).
Glucose, insulin, and PTT. At the time of performing insulin tolerance tests (ITT),
mice were 11 weeks of age and either 4 weeks exposed to CD or HFD feeding. ITT
was carried out in random-fed mice in the morning. After determining basal blood
glucose levels, each animal received 0.75 IU per kg BW of insulin (Insuman Rapid;
Sanofi-Aventis). For glucose tolerance tests (GTT), mice were 12 weeks of age and
5 weeks exposed to CD or HFD feeding. After 16 h of fasting and measurement of
basal blood glucose levels, animals were i.p. injected with 2 g per kg BW of glucose
(20% glucose, Delta select). Blood glucose levels were recorded using an automatic
glucose monitor (Contour, Bayer Diabetes Care) at the indicated time points in (1)
male Scr vs. Mafg and LincIRS2 LNA-treated mice, (2) Control ASO vs. Mafg ASO,
and (3) LincIRS2wt/wt (Control for LincIRS2Δ/Δ) and LincIRS2Δ/Δ mice. In the ASO
cohort, animals that showed no decrease of blood glucose after insulin gavage
throughout all measurements were excluded from ITT analysis, assuming injection
of insulin outside of the peritoneal cavity as required for the assay. The pyruvate
tolerance test (PTT) was performed in HFD-fed animals after 6 weeks of HFD
feeding with Scr andMafg LNA injection 5 days before the experiment. For the PTT
itself, 4 g of pyruvate was dissolved in 20ml of 0.9% NaCl and injected 10 µl g−1 BW
after 16 h of fasting (final dose 2 g pyruvate kg−1).
Indirect calorimetry (PhenoMaster). Upon indirect calorimetry measurements,
mice of indicated genotypes and diets were 16 weeks of age and 10 weeks exposed
to CD or HFD. All measurements were performed using a PhenoMaster System
(TSE Systems), which allowed in-cage metabolic and activity monitoring. Three
days before analysis, mice were placed alone in training cages, identical to the 7.1-l
chambers of the PhenoMaster open-circuit calorimetry system and continued to
receive the respective diets (CD and HFD) throughout training and data acquisi-
tion. Diets and water were provided AL in the appropriate devices, and food intake
measured by the built-in automated instruments. Parameters of indirect
Fig. 6 CRISPR-mediated deletion of LincIRS2 impairs glucose metabolism in lean mice. a Fasted and random-fed glucose in CD-fed 12-week-old
LincIRS2Δ/Δ mutant mice (n= 8) vs. wild-type littermates (n= 11). b ITT in 11-week-old and c GTT in 12-week-old, CD-fed LincIRS2Δ/Δ (n= 8) vs. Control
mice (n= 11). d–g qPCR of d gluconeogenic e oxidative f IR signaling and g glucose transporter expression in 8–15-week-old LincIRS2Δ/Δ vs. LincIRS2Δ/wt
(n= 8) mice. h Hepatic qPCR and immunoblot (n= 4) from 18- to 20-week-old C57BL/6N 10 weeks after i.v. injection with 1× 10E11 genomic copies/
animal encoding AAV8-CTRL or AAV8-MAFG. Fasted i and random-fed j glucose. k, l GTT and m, n ITT in CD-fed 18–20-week-old LincIRS2Δ/Δ vs. C57BL/
6N Controls (n= 12 each) with half of mice in each genotype (n= 6) i.v. injected with 1× 10E11 genomic copies/animal AAV8-CTRL or AAV8-MAFG.
o Illustration of MAFG and LincIRS2 in regulation of hepatic glucose metabolism. Bar graphs represent mean ± s.e.m. with all data plotted and statistical
differences were calculated using a, d–h unpaired, two-tailed Student’s t test. i, j One-way ANOVA with Bonferroni post correction for multiple testing.
b, c, k–n Two-way ANOVA with Bonferroni post correction for multiple testing. Superscripts depict group comparisons for post analysis (a–f= comparison
vs. columns 1–6) *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
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calorimetry were measured initially for 96 h at 22 °C and mean values calculated for
each time of day.
Tissue collection. At the end of the experimental protocol, LNA-injected mice
were randomly assigned to either intravenous (i.v.) injection of 0.9% NaCl or
0.1 U/animal of insulin (Sigma). All mice were sacrificed by carbon dioxide (CO2)
asphyxiation. All tissues were washed with 1× PBS, weighed, snap-frozen in liquid
nitrogen, and stored at −80 °C.
Enzyme-linked immunosorbent assay. Fibroblast Growth Factor 21 Mouse
(FGF21) ELISA was obtained from Biovendor RD291108200R (Czech Republic),
and performed using serum from CD and HFD-fed mice, Scr vs. Mafg LNA treated
following the manufacturer’s instructions.
Histological staining. For immunostaining, liver tissues were stored in PFA 4% for
24 h and then 70% ethanol for histological analysis. Transveral cryosections from
paraffin-embedded liver were prepared, fixed, and stained by hematoxylin and
eosin (H/E).
RNA isolation and quantitative RT-PCR (qPCR) analysis. Total RNA was iso-
lated from primary hepatocytes and whole tissues using peqGOLD TriFast (PEQ-
LAB Biotechnologie). mRNA was reverse transcribed into complementary DNA
using High Capacity cDNA reverse transcription kit (Applied Biosystems). Abun-
dances of mRNAs were quantified by TaqMan Assay on Demand Kits (Applied
Biosystems) according to the manufacturer’s protocol if not indicated otherwise.
Abundances of lncRNAs were quantified using SYBR methodology using Select
Master Mixes (Thermo Fisher). The relative abundance of mRNAs was calculated
using comparative methods (2−ΔΔCT) according to ABI Relative Quantification
Methods. Transcript levels were normalized to hypoxanthine phosphoribosyl-
transferase 1 (Hprt1) or glyceraldehyde-3-phosphate dehydrogenase (Gapdh)
expression; Hprt and Gapdh abundances remained unaffected across experimental
conditions. SYBR primer sequences are provided in Supplementary Data 10.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Fig. 1c–i, Fig. 2b, d, e, g, i, Fig. 3a–h, Fig. 4a–j, l–r, Fig. 5a–r,
Fig. a–n, and Supplementary Fig. 1d–f, h–I, Fig. 2c–k, Fig. 3a–g, i–j, Fig. 4b, k–n,
Fig. 5a–b, e are provided as Source Data file. Data from RNA-Seq are available under
GEO Super Series GSE121346.
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